Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring

卷:8

David Ames¹  Olivier Salvado²  Ralph N. Martins³  Stephanie Rainey‐Smith³  Jason Hassenstab⁴  Simon M. Laws⁵  Vincent Doré⁶  Christopher C. Rowe⁶  Peter J. Snyder⁷  Victor L. Villemagne⁸  Paul Maruff⁸  Karra D. Harrington⁸  AIBL Research Group⁸  Joanne Robertson⁸  Yen Ying Lim⁸  Colin L. Masters⁸ 

[1] Academic Unit for Psychiatry of Old Age, Department of PsychiatryThe University of MelbourneParkvilleVictoriaAustralia;

[2] CSIRO Health and BiosecurityThe Australian eHealth Research CentreBrisbaneQueenslandAustralia;

[3] Centre of Excellence for Alzheimer's Disease Research and CareSchool of Exercise, Biomedical and Health Sciences, Edith Cowan UniversityPerthWestern AustraliaAustralia;

[4] Charles F. and Joanne Knight Alzheimer's Disease Research CenterWashington University School of MedicineSt. LouisMOUSA;

[5] Cooperative Research Centre for Mental HealthParkvilleVictoriaAustralia;

[6] Department of Molecular ImagingAustin HealthMelbourneVictoriaAustralia;

[7] Department of NeurologyWarren Alpert School of Medicine, Brown UniversityProvidenceRIUSA;

[8] The Florey Institute, The University of MelbourneParkvilleVictoriaAustralia;

关键词: Alzheimer disease;    Amyloid;    Cognitive aging;    Normal aging;    Memory;   

DOI  :  10.1016/j.dadm.2017.05.006

来源: DOAJ

【 摘 要 】

Abstract Introduction High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.

【 授权许可】

Unknown